PTC Therapeutics is hoping that a recommendation by the European Medicines Agency to update the label of its approved Duchenne muscular dystrophy (DMD) treatment, Translarna (ataluren), will lead to improved patient access and reimbursement for the product across Europe.
The update aims to prevent reimbursement agencies from misinterpreting Translarna’s label and ceasing access to the drug in boys who...







